These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9655890

  • 1. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.
    Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis KM, Stecker KK, Martin MJ, Crooke RM.
    J Pharmacol Exp Ther; 1998 Jul; 286(1):447-58. PubMed ID: 9655890
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS, Leeds JM, Fitchett J, Burckin T, Truong L, Spainhour C, Creek M, Levin AA.
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M, Hayes CS, Chappell A, Murray SF, Yaksh TL, Hua XY.
    Neuroscience; 2005 Nov; 131(3):705-15. PubMed ID: 15730875
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE.
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion.
    Soucy NV, Riley JP, Templin MV, Geary R, de Peyster A, Levin AA.
    Birth Defects Res B Dev Reprod Toxicol; 2006 Feb; 77(1):22-8. PubMed ID: 16496297
    [Abstract] [Full Text] [Related]

  • 10. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues.
    Butler M, Stecker K, Bennett CF.
    Lab Invest; 1997 Oct; 77(4):379-88. PubMed ID: 9354772
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
    Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR.
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
    [Abstract] [Full Text] [Related]

  • 13. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
    Geary RS, Khatsenko O, Bunker K, Crooke R, Moore M, Burckin T, Truong L, Sasmor H, Levin AA.
    J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
    [Abstract] [Full Text] [Related]

  • 14. Biodistribution and hepatic uptake of triplex-forming oligonucleotides against type alpha1(I) collagen gene promoter in normal and fibrotic rats.
    Cheng K, Ye Z, Guntaka RV, Mahato RI.
    Mol Pharm; 2005 Mar; 2(3):206-17. PubMed ID: 15934781
    [Abstract] [Full Text] [Related]

  • 15. Metabolism of antisense oligonucleotides in rat liver homogenates.
    Crooke RM, Graham MJ, Martin MJ, Lemonidis KM, Wyrzykiewiecz T, Cummins LL.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):140-9. PubMed ID: 10604941
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M, Levin AA.
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.
    Phillips JA, Craig SJ, Bayley D, Christian RA, Geary R, Nicklin PL.
    Biochem Pharmacol; 1997 Sep 15; 54(6):657-68. PubMed ID: 9310342
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
    Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA.
    Drug Metab Dispos; 2003 Nov 15; 31(11):1419-28. PubMed ID: 14570775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.